Lantheus is a drug manufacturers - specialty & generic business based in the US. Lantheus shares (LNTH) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $108.74 – an increase of 6.85% over the previous week. Lantheus employs 808 staff and has a trailing 12-month revenue of around $1.5 billion.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $108.74 |
|---|---|
| 52-week range | $65.89 - $126.89 |
| 50-day moving average | $96.38 |
| 200-day moving average | $99.03 |
| Wall St. target price | $134.38 |
| PE ratio | 23.3417 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $4.36 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $105.92 from 2025-05-01
| 1 week (2025-04-25) | 4.08% |
|---|---|
| 1 month (2025-04-04) | 16.50% |
| 3 months (2025-02-04) | 15.38% |
| 6 months (2024-11-04) | -8.25% |
| 1 year (2024-05-03) | 40.24% |
|---|---|
| 2 years (2023-05-03) | 28.37% |
| 3 years (2022-05-03) | 61.34% |
| 5 years (2020-05-01) | 777.55% |
Valuing Lantheus stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Lantheus's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Lantheus's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 23x. In other words, Lantheus shares trade at around 23x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Lantheus's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.61. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Lantheus's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Lantheus's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $510.5 million.
The EBITDA is a measure of a Lantheus's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $1.5 billion |
|---|---|
| Operating margin TTM | 28.23% |
| Gross profit TTM | $988.3 million |
| Return on assets TTM | 15.35% |
| Return on equity TTM | 32.82% |
| Profit margin | 20.37% |
| Book value | $15.90 |
| Market Capitalization | $7.1 billion |
TTM: trailing 12 months
We're not expecting Lantheus to pay a dividend over the next 12 months.
Over the last 12 months, Lantheus's shares have ranged in value from as little as $65.8914 up to $126.8899. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lantheus's is 0.196. This would suggest that Lantheus's shares are less volatile than average (for this exchange).
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .